Rani Therapeutics Holdings, Inc.

Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company. The Company is focused on advancing technologies to enable the administration of biologics and drugs orally, to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. It has developed a drug-agnostic oral delivery platform, the RaniPill capsule, which is designed to deliver a variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. The RaniPill GO, is designed to deliver up to a three micrograms (mg) dose of drug with high bioavailability. The capsule includes a coating designed to withstand stomach acid but dissolve in the jejunum portion of the small intestine. Its pipeline includes RT-102, RT-105, RT-111 and RT-110. It is also developing a high-capacity version of the RaniPill capsule known as the RaniPill HC, which is intended to enable delivery of drug payloads up to 200uL in liquid form with high bioavailability.